Jiang-Ping Wu
Boehringer Ingelheim
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jiang-Ping Wu.
Bioorganic & Medicinal Chemistry Letters | 2008
Daniel R. Goldberg; Younggi Choi; Derek Cogan; M. Corson; Rodney P. DeLeon; Amy Gao; L. Gruenbaum; Ming-Hong Hao; D. Joseph; Mohammed A. Kashem; Craig Andrew Miller; Neil Moss; Matthew R. Netherton; Chris Pargellis; Josephine Pelletier; Rosemarie Sellati; Donna Skow; Carol Torcellini; Y.-C. Tseng; Ji Wang; R. Wasti; Brian Werneburg; Jiang-Ping Wu; Zhaoming Xiong
Optimization of pyrazinoindolone inhibitors of MAPKAP-K2 (MK2) provides a reasonable balance of cellular potency and physicochemical properties. Mechanistic studies support the inhibition of MK2 which is responsible for the sub-micromolar cellular efficacy.
Bioorganic & Medicinal Chemistry Letters | 2009
Jiang-Ping Wu; Roman Wolfgang Fleck; Janice R. Brickwood; Alison Capolino; Katrina Mary Catron; Zhidong Chen; Charles L. Cywin; Jonathan Emeigh; Melissa Foerst; John David Ginn; Matt Hrapchak; Eugene R. Hickey; Ming-Hong Hao; Mohammed A. Kashem; Jun Li; Weimin Liu; Tina Marie Morwick; Richard M. Nelson; Daniel R. Marshall; Leslie Martin; Peter Allen Nemoto; Ian Potocki; Michel Liuzzi; Gregory W. Peet; Erika Scouten; David Stefany; Michael Robert Turner; Steve Weldon; Clare Zimmitti; Denise Spero
An SAR study that identified a series of thienopyridine-based potent IkappaB Kinase beta (IKKbeta) inhibitors is described. With focuses on the structural optimization at C4 and C6 of structure 1 (Fig. 1), the study reveals that small alkyl and certain aromatic groups are preferred at C4, whereas polar groups with proper orientation at C6 efficiently enhance compound potency. The most potent analogues inhibit IKKbeta with IC50s as low as 40 nM, suppress LPS-induced TNF-alpha production in vitro and in vivo, display good kinase selectivity profiles, and are active in a HeLa cell NF-kappaB reporter gene assay, demonstrating that they directly interfere with the NF-kappaB signaling pathway.
Bioorganic & Medicinal Chemistry Letters | 2016
Asitha Abeywardane; Gary O. Caviness; Younggi Choi; Derek Cogan; Amy Gao; Daniel R. Goldberg; Alexander Heim-Riether; Debra Jeanfavre; Elliott S. Klein; Jennifer A. Kowalski; Wang Mao; Craig Andrew Miller; Neil Moss; Philip Dean Ramsden; Ernest L. Raymond; Donna Skow; Lana Smith-Keenan; Roger J. Snow; Frank Wu; Jiang-Ping Wu; Yang Yu
Compound 1 ((4-amino-3,5-dichlorophenyl)-1-(4-methylpiperidin-1-yl)-4-(2-nitroimidazol-1-yl)-1-oxobutane-2-sulfonamido) was discovered to be a 690nM antagonist of human CCR10 Ca2+ flux. Optimization delivered (2R)-4-(2-cyanopyrrol-1-yl)-S-(1H-indol-4-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutane-2-sulfonamido (eut-22) that is 300 fold more potent a CCR10 antagonist than 1 and eliminates potential toxicity, mutagenicity, and drug-drug-interaction liabilities often associated with nitroaryls and anilines. eut-22 is highly selective over other GPCRs, including a number of other chemokine receptors. Finally, eut-22 is efficacious in the murine DNFB model of contact hypersensitivity. The efficacy of this compound provides further evidence for the role of CCR10 in dermatological inflammatory conditions.
Archive | 2003
Charles L. Cywin; Zhidong Chen; Jonathan Emeigh; Roman Wolfgang Fleck; Ming Hong Hao; Eugene R. Hickey; Weimin Will Liu; Daniel R. Marshall; Tina Marie Morwick; Peter Allen Nemoto; Ronald John Sorcek; Sanxing Sun; Jiang-Ping Wu
Archive | 2000
Jiang-Ping Wu; Terence A. Kelly; Rene Marc Lemieux; Daniel R. Goldberg; Jonathan Emeigh; Ronald John Sorcek
Journal of Medicinal Chemistry | 2004
Jiang-Ping Wu; Jonathan Emeigh; Donghong A. Gao; Daniel R. Goldberg; Daniel Kuzmich; Clara K. Miao; Ian Potocki; Kevin Chungeng Qian; Ronald John Sorcek; Deborah D. Jeanfavre; Kei Kishimoto; Elizabeth Mainolfi; Gerald H. Nabozny; Charline Peng; Patricia L. Reilly; Robert Rothlein; Rosemarie Sellati; Joseph R. Woska; Shirlynn Chen; Jocelyn A. Gunn; Drane O'Brien; and Stephen H. Norris; Terence A. Kelly
Organic Letters | 2005
Jiang-Ping Wu; Jonathan Emeigh; Xi-Ping Su
Archive | 1999
Terence A. Kelly; Barbara J. Bormann; Leah Lynn Frye; Jiang-Ping Wu
Archive | 2000
Terence A. Kelly; Jiang-Ping Wu; Daniel Kuzmich; Yancey David Ward; Leah Lynn Frye
Archive | 2009
Derek Cogan; Alexander Heim-Riether; Wang Mao; Craig Andrew Miller; Philip Dean Ramsden; Lana Louise Smith Keenan; Roger J. Snow; Jiang-Ping Wu; Yu Yang